Eli Lilly and Company (LLY) News Today

Eli Lilly and Company (NYSE: LLY) shares are benefiting from strong third-quarter results, higher guidance and encouraging data for its next-generation obesity treatment, retatrutide. The stock is trading near its 52-week high, supported by robust growth in Lilly’s GLP-1 franchise.

• Positive Sentiment: Strong Q3 performance and raised outlook: Third-quarter revenue rose 39% year over year to $24.4 billion, driven primarily by Mounjaro and Zepbound. Lilly also raised its full-year guidance, reinforcing expectations for continued demand in diabetes and obesity treatments. Results included approximately $900 million in favorable items, including a $410 million Jardiance milestone and rebate-related adjustments; the company said no further Jardiance milestones remain. Lilly third-quarter 2026 financial results
• Positive Sentiment: Retatrutide data strengthens Lilly’s pipeline: In a Phase 3 diabetes trial, retatrutide reduced A1C by an average of 2.2%, versus 1.8% for Ozempic 2 mg, while patients lost roughly 20%–21% of body weight, more than twice the weight loss reported for Ozempic. The results increase the drug’s potential to extend Lilly’s competitive lead in obesity care, although regulatory approval is still required. Retatrutide Phase 3 trial results
• Positive Sentiment: Additional commercial and regulatory support: A court rejected Novo Nordisk’s effort to block Lilly’s obesity-drug advertising, while regulatory progress across Lilly’s portfolio and expansion in neuroscience and immunology provide potential growth beyond GLP-1 medicines.
• Neutral Sentiment: Management transition: International-business chief Patrik Jonsson will retire at year-end, with Ilya Yuffa taking over the expanded Lilly Global Markets role on January 1, 2027. The transition is planned, but investors will monitor execution as Lilly scales globally.
• Negative Sentiment: Risks remain: Employer concerns about covering costly weight-loss drugs, pricing pressure, competition and Lilly’s elevated valuation could limit further upside. The company also faces a lawsuit alleging patient-privacy risks, adding a legal overhang.